Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$23.52M-13.2%-$20.77M+3.5%-$21.53M-1.3%-$21.25M-4.6%-$20.31M-26.2%
$666K0.0%$666K+0.6%$662K+3.3%$641K+2.1%$628K+2.3%
$1.59M+0.3%$1.59M-2.6%$1.63M+5.3%$1.55M-24.5%$2.05M-6.0%
-$20.95M-42.3%-$14.73M+23.3%-$19.2M+16.5%-$22.98M-15.8%-$19.84M-35.4%
$242K-42.5%$421K-29.8%$600K-43.1%$1.06M+106%$511K+698%
$15.32M-4.5%$16.04M-1.5%$16.28M-22.9%$21.12M+112%$9.97M+1,132%
-$112K$239K
-$5.75M$0+100%-$2.96M-53.1%-$1.93M+79.9%-$9.63M+38.4%
-$21.19M-39.9%-$15.15M+23.5%-$19.8M+17.6%-$24.04M-18.1%-$20.35M-38.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Artiva Biotherapeutics, Inc. generate?
Artiva Biotherapeutics, Inc. (ARTV) generated -$77.9M in operating cash flow over the trailing twelve months.
What is Artiva Biotherapeutics, Inc.'s free cash flow?
After $2.3M of capital expenditures, Artiva Biotherapeutics, Inc.'s free cash flow was -$80.2M over the trailing twelve months, down 31.6% year over year.
Where does Artiva Biotherapeutics, Inc.'s cash flow data come from?
Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.